| Abstract|| |
We evaluated in this study the effects of regular use of maintenance intravenous (IV) iron saccharate on the hematological parameters, iron stores, and erythropoietin (EPO) requirement in a group of stable hemodialysis (HD) patients. We maintained 34 stable HD patients (14 (41.2%) males) with a mean age of 43.1 ±16 years (range 17-69) and mean duration of HD of 39.3 ± 34.5 months on EPO. We also added 50-100 mg IV iron saccharate every week during a 6-month period from May-October, 1999. At entry, 18 (47.1%) patients required loading doses of IV iron saccharate. We compared the results at entry with those at six months. The mean hemoglobin increased significantly from 97 ± 10 to 117 ± 20 g/l, (p<0.0001), serum ferritin increased significantly from a mean of 160 ± 224 to 377 ± 216 ng/ml, (p<0.0001), transferrin saturation increased from 21 ±1.9 to 28 ± 8 %, (p= .0002), EPO dose decreased significantly from a mean weekly dose of 8800 ± 3200 to 5500 ± 3000 units (p=0.002). The cost saving analysis suggested an annual savings of 6448 Saudi Riyals (1719 US $) per patient attributable to reduction in the administered EPO dose. We conclude that IV iron saccharate use to replenish and maintain iron stores in stable EPO treated HD patients is safe and effective. It results in achieving target hemoglobin with significantly lower doses of EPO.
Keywords: Renal anemia, Hemodialysis, Iron saccharate, Erythropoietin.
|How to cite this article:|
Al-Mueilo SH. Beneficial Effects of Maintenance Intravenous Iron Saccharate in Hemodialysis Patients. Saudi J Kidney Dis Transpl 2005;16:146-53
|How to cite this URL:|
Al-Mueilo SH. Beneficial Effects of Maintenance Intravenous Iron Saccharate in Hemodialysis Patients. Saudi J Kidney Dis Transpl [serial online] 2005 [cited 2021 May 8];16:146-53. Available from: https://www.sjkdt.org/text.asp?2005/16/2/146/32933
| Introduction|| |
Anemia is present in the majority of end-stage renal disease (ESRD) patients commencing regular hemodialysis (HD).  Untreated, anemia in renal patients is associated with several functional and structural abnormalities. These include decreased cognitive function,  impaired exercise capacity, defective immune system, , left ventricular hypertrophy, increased cardiac output, angina and congestive heart failure. , Although several factors may be operative in the genesis of renal anemia, insufficient production of erythropoietin (EPO) by the diseased kidneys is by far most significant. ,,
The availability of recombinant human erythropoietin (EPO) in the late 1980's of the last millennium had revolutionized the management of anemia in HD, peritoneal dialysis and pre-dialysis patients. ,, Erythropoietin induced correction of anemia in ESRD patients is associated with several favorable outcomes. Such correction is associated with improved quality of life parameters,  better cognitive function,  relief of some of the uremic symptoms such as pruritus,  improved lipid profile,  and reduced left ventricular mass index and decreased mortality. , Hyporesponsiveness to EPO is occasionally encountered among chronic HD patients and is attributable to several factors, of which absolute and/or functional iron deficiency is the most prevalent.  Absolute iron deficiency in EPO treated HD patients is diagnosed when serum ferritin is less than 100 ng/ml and percentage transferring saturation (TSAT) is less than 20%. Functional iron deficiency refers to the need for a greater amount of iron to support hemoglobin synthesis than can be released from the reticuloendothelial cells and is diagnosed when TSAT is less than 20% in the presence of serum ferritin greater than 100 ng/ml.  Hemodialysis associated iron losses from blood sampling, dialyzer clotting, blood in the dialysis circuit, and post dialysis bleeding are estimated to amount to two grams annually.  In order to sustain EPO induced erythropoiesis and to compensate for these losses, a positive iron balance has to be established. Oral iron therapy is commonly ineffective in this respect. ,, Reasons behind inadequacy of oral iron therapy include in efficient gastrointestinal (GI) absorption, , GI side effects and drugs interactions.  Parenteral iron therapy is the preferred route of administration. ,, Clinical practice is not uniform with respect to type of parenteral iron preparations and dosing strategies. ,,,,,
In this report, we evaluate the effects of regular use of maintenance IV iron saccharate on the hematological parameters, iron store, and EPO requirement in a group of stable HD patients. Additionally, we attempt to analyze the potential cost savings from implementing the study findings.
| Patients and Methods|| |
This is an open-label prospective study on the use of IV iron saccharate (Ferosac®, Spimaco, Saudi Arabia) in adult HD patients that we performed at King Fahd Hospital of the University (KFHU), Alkhobar, Saudi Arabia from May-October, 1999. The patients included in the study are end-stage renal disease patients who had been on regular maintenance hemodialysis and on subcutaneous EPO (Eprex®, pre-filled syringes, Cilag AG international 6300 Zug, Switzerland) for at least six months.
None of the patients had received IV iron prior to enrollment. The majority of the patients were on oral iron. Patients with active infection, inflammation or gastrointestinal bleeding were excluded. At time of entry to the study and once a month thereafter, hemoglobin (Hgb), hematocrit (Hct) and TSAT were obtained. Serum B12 level, serum folate and RBC folate were determined at baseline.
The average weekly dose of EPO before enrollment into the trial and for every month thereafter was determined from patients' records. Efficiency of dialysis was estimated by calculating the urea reduction ratio (URR) at baseline and every month.
At onset of the study, we stopped the oral iron therapy and initiated IV iron saccharate protocol and monitored the status of the iron stores. If serum ferritin was > 100 ng/ml and TSAT > 20%, a weekly dose of 50-100 mg iron saccharate infused intravenously over 10 minutes in the venous limb of the vascular access after dialysis was commenced. On the other hand, if the patient was iron deficient as defined by serum ferritin < 100 ng/ml and/ or TSAT < 20%, a loading cumulative dose of 500-1200 mg iron saccharate divided to 100 mg doses post dialysis. This was followed by a maintenance dose of 50-100 mg IV post dialysis once/week. Iron saccharate was held whenever serum ferritin exceeded 800 ng/ml and resumed when the serum level decreased below 600 ng/ml. EPO was administered subcutaneously after dialysis 1-3 times/week. The pretrial EPO dose was kept the same during the first month of IV iron therapy. The level of Hgb/Hct guided further adjustment of EPO dose. When Hgb exceeds 12 gm/dl, the EPO dose was reduced by 25%. If Hct increased less than 2% over 2-4 weeks, the EPO dose was increased by 25%. The effects of iron therapy were monitored by changes in Hgb, Hct, serum ferritin level, TSAT and average weekly EPO dose every month during the six months of the study.
A cost saving analysis was performed based on the acquisition cost for EPO and iron saccharate by (KFHU) in Saudi Riyal (SR), (exchange rate is 1 US$ = 3.75 SR). The cost of erythropoietin was 160 SR (42.7 US$) for each 4000 prefilled syringe. The acquisition cost of iron saccharate is estimated at 15 SR (4 US$) per 100 mg ampoule. Changes in EPO cost were estimated based on the difference in dose at the start and end of the study. The cost of iron saccharate was subtracted from any potential savings from changes in EPO dosing. The cost associated with overhead, physician and nurse time were not included in the analysis.
| Statistical Analysis|| |
Data are represented as mean ± SD. Each patient was used as his/her own prospective control. Hgb, Hct, serum ferritin, TSAT, weekly EPO dose and URR were analyzed with Student's paired t-test to compare the pretrial values with values at 3 and 6 months. Probability (p) value < 0.05 was considered as statistically significant.
| Results|| |
Thirty-four patients with ESRD on HD were enrolled in the study. There were 14 males (41.2%); mean age of the whole group was 43.1 ± 16 years (range 17-69). All patients were on bicarbonate mode of HD for 3-4 hours, 3 sessions / week. All patients were receiving EPO subcutaneously, with an average weekly dose of 8800 ± 3200 units. The average duration of HD before entering the study was 39.3 ± 34.5 months (range 6-118). Twenty-eight (82.4%) patients were on oral iron therapy, which was stopped at the start of the study. None of the patients had evidence of B12 or folate deficiency at time of entry.
At entry 18 (47.1%) patients received loading doses of 500-1200 mg iron saccharate given as IV infusion over 10 minutes after dialysis in divided doses of 100 mg each session after an initial test IV dose of 25 mg; one of these patients subsequently required a second loading dose of 500mg. this was followed by weekly supplemental IV iron saccharate of 50-100 mg. The remainder of the patients received the maintenance dose since the start of the study. At 6 months, 32 patients were receiving 50 mg/week and two patients were on 100mg/ week.
We compared the results at entry with those at six months. The mean hemoglobin increased significantly from 97 ± 10 to 117 ± 20 g/l, (p<0.0001), serum ferritin increased significantly from a mean of 160 ± 224 to 377 ± 216 ng/ml, (p<0.0001), transferrin saturation increased from 21 ±1.9 to 28 ± 8 %, (p= .0002). In fact, the changes in these parameters were already evident at three months from initiation of the IV iron saccharate therapy, [Table - 1].
At the time of entry 18 patients (53%) had serum ferritin <100 ng/ml, and 20 patients (58.8%) had TSAT < 20%. By the end of 6 months these had decreased to three patients (8.8%) and six patients (17.6%), respectively.
Concomitant with these favorable changes, the administered EPO dose decreased significantly from a mean weekly dose of 8800 ± 3200 units at entry to 7800 ± 3400 units at three months, (p=0.02) and 5500 ± 3000 units at 6 months, (p=0.002). The efficiency of hemodialysis treatments as judged by the URR had not significantly changed during the study period.
The mean iron saccharate consumed dose was 144, 69 and 54.4 mg /patient /week at one, three and six months of therapy. No adverse reactions attributable to iron saccharate infusions were observed in any of the patients. There was no noted increase in the incidence of infectious episodes among the patients during the study period.
In the first month of the study, there was a 6.1% increase in the cost due to the loading doses of iron saccharate used to optimize iron stores. However, the significant reduction in the required EPO dose quickly negated this added cost. At six months of the study, there was a 35% decrease in the cost associated with EPO use, when compared to the cost prior to the study. The savings at the end of the study was calculated to be 124 SR / patient /week and the projected annual saving would be 6448 SR per patient (1719 US$ per patient).
In a subgroup of nine patients (three males and six females with a mean age of 40.2 ± 18 years and mean duration on HD of 34.8 ± 37.8 months) who were iron replete as defined by serum ferritin and TSAT greater than 100 ng/ml and 20% respectively, the intravenous weekly maintenance iron saccharates resulted in an increase in serum ferritin from 185.8 ± 80.7 at baseline to 445.1 ± 177.9 ng/ml at 6 months (p= 0.001). Mean hemoglobin increased from 10.1 ± 1.3 at base-line to 11.6 ± 1.9 gm/dl at 6 months. Over the same period mean administered EPO dose decreased from 7900 ± 3500 to 7000 ± 3900 units/ patient/ week; a decrease of 11.2%. However the changes in Hgb and mean EPO dose were not statistically significant.
| Discussion|| |
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines have recommended target Hgb (Hct) of 11g/dl (33%) to Hgb 12 g/dl (36%) in most EPO treated HD patients.  This recommendation is based on the noted decreased quality of life and increased morbidity and mortality in chronic kidney disease patients as Hgb/Hct falls below 10 (33%). ,,,, Since oral iron supplementation is usually insufficient to reach these targets, parenteral iron is necessary in HD patients treated with EPO. ,,
Iron dextran has been associated with serious side effects such as anaphylactoid reactions and even death in rare instances.  The wider availability of other IV iron preparations such as iron gluconate and iron saccharate (sucrose) has simplified iron management in HD patients with a better safety profile than iron dextran. ,,,,
The recent introduction of heme-iron polypeptides (HIP) is promising. These oral iron preparations are absorbed to a greater extent, and are better tolerated. Use of HIP in EPO treated HD patients during a 6-month open prospective trial maintained target Hgb without the need for concomitant use of IV iron.  However, 4 of 37 (11%) patients in this trial dropped out because of side effects or insufficient iron supplementation. Wider acceptance of these compounds in clinical practice awaits confirmation of safety and efficacy from larger and longer clinical trials.
Our study demonstrates that adopting an IV iron saccharate protocol in HD patients is safe, effective and economically cost effective. Significant increase in the Hgb, Hct, ferritin, and TSAT was observed at the end of the study coupled with a remarkable reduction in the administered EPO dose.
Several investigators had reported similar benefits. ,,,, Park et al  treated 30 iron deficient HD patients on EPO with IV loading dose of 1gm iron dextran in five divided doses followed by a monthly dose of 100 mg during a 4-month study period. At the end of the 4month study, mean serum ferritin and TSAT had increased significantly from 49 ng/ml to 225 ng/ml and 27% to 33%, respectively. Values for hemoglobin did not change significantly during the study period; however, there was a significant reduction in EPO dose from a mean baseline dose of 112 U/kg/wk to 88 U/kg/wk at the end of the study. The authors' economic analysis suggested that approximately 580 Canadian $/ patient/ year could be saved by use of IV iron dextran. Furthermore, Macdougall et al  administered a weekly IV bolus of 100 mg iron sucrose to 116 HD patients with low serum ferritin. At 12 months, mean serum ferritin and hemoglobin level significantly increased from 214 ng/ml to 564 ng/ml and from 9.6 g/dl to 10.7 g/dl, respectively. Over the same period, there was a dramatic 32.4 % reduction in mean EPO dose. This resulted in cost savings of approximately 244 US$/ patient/ month.
Intravenous maintenance iron therapy may be worthwhile even in iron replete EPO treated HD patients. Chang CH et al  conducted a 12-month intravenous iron substitution trial in 149 iron-replete chronic HD patients (mean serum ferritin 930 ± 857 ng/ml) receiving subcutaneous EPO therapy. The available iron pool was maintained with 100 mg iron every 2 weeks or 1 month depending on serum ferritin and TSAT levels. After 12 months, the mean Hct increased significantly from 27.7 to 28.7 %. The mean serum ferritin and TSAT also increased significantly. EPO requirement could be reduced by 25%. The estimated cost saving on EPO administration was around 400US$ / patient/ year.
We had similar findings in our patients who were iron replete as defined by serum ferritin and TSAT greater than 100 ng/ml and 20% respectively. However, due to the small size sample, changes in Hgb and mean EPO dose were not statistically significant.
Finally, there is theoretical potential risk of iron maintenance therapy such as risk of infection and atherosclerotic cardiovascular disease. However, clinical studies so far do not show such increased risk. ,, The benefits of intravenous iron therapy outweigh the potential risks in most HD patients. However, careful monitoring is essential to ensure safety and success of IV iron policy in HD patients.
In conclusion, the use of intravenous iron saccharate to replenish and maintain iron stores in stable EPO treated HD patients is safe and effective. It results in achieving target Hgb with significantly lower doses of EPO. There fore, significant EPO related cost saving can be accomplished by implementation of IV iron therapy protocol.
| Acknowledgement|| |
We wish to thank Prof. Fahd Al-Muhanna and Dr. Ibrahim Saeed for their help and support in carrying out the study. I also thank Mrs. Ezdehar Barbari, Mrs. Daisy Donesa and the nursing staff at KFHU hemodialysis unit for their assistance in implementing the protocol and data collection.
| References|| |
|1.||Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int 1985;28:1-5. [PUBMED] |
|2.||Wolcott DL, Marsh JT, La Rue A, Carr C, Nissenson AR. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 1989;14:478-85. [PUBMED] |
|3.||Gafter U, Kalechman Y, Orlin JB, Levi J, Sredni B. Anemia of uremia is associated with reduced in vitro cytokine secretion: Immunopotentiating activity of red blood cells. Kidney Int 1994;45:224-31. [PUBMED] |
|4.||Vanholder R, Van Biesen W, Ringoir S. Contributing factors to the inhibition of phagocytosis in hemodialyzed patients. Kidney Int 1993;44:208-14. [PUBMED] |
|5.||Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47:884-90. [PUBMED] |
|6.||Wizemann V, Kaufmann J, Kramer W. Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992;62:161-5. |
|7.||Cannella G, La Canna G, Sandrini M, et al. Renormalization of high cardiac output and of left ventricular size following longterm recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clin Nephrol 1990;34:272-8. |
|8.||Hakim RM, Lazarus JM. Biochemical parameters in chronic renal failure. Am J Kidney Dis 1988;11:238-47. [PUBMED] |
|9.||Chandra M, Clemons GK, McVicar MI. Relation of serum erythropoietin levels to renal excretory function: evidence for lowered set point for erythropoietin production in chronic renal failure. J Pediatr 1988;113: 1015-21. [PUBMED] |
|10.||McGonigle RJ, Boineau FG, Beckman B, et al. Erythropoietin and inhibitors of in vitro erythropoiesis in the development of anemia in children with renal disease. J Lab Clin Med 1985;105:449-58. [PUBMED] |
|11.||Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2:1175-8. [PUBMED] |
|12.||Nissenson AR, Korbet S, Faber M, et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 1995;5:1517-29. [PUBMED] |
|13.||Lim VS, DeGowin RL, Zauala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients: A doubleblind placebo controlled trial. Ann Intern Med 1989;110:108-14. |
|14.||Benz RL, Pressman MR, Hovick ET, Peterson DD. A preliminary study of the effects correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients: The SLEEPO Study. Am J Kidney Dis 1999; 34:1089-95. [PUBMED] |
|15.||De Marchi S, Cecchin E, Villalta D, Sepiacci G, Santini G, Bartoli E. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Eng J Med 1992; 326:969-74. |
|16.||Pollock CA, Wyndham R; Collett PV, et al. Effects of erythropoietin therapy on the lipid profile in end-stage renal failure. Kidney Int. 1994;45:897-902. |
|17.||Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-9. [PUBMED] [FULLTEXT]|
|18.||Macdougall IC. Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 1995;10:607-14. |
|19.||Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996;7:2654-7. [PUBMED] |
|20.||Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron balance in hemodialysis patients. Ann Intern Med 1977;87:710-3. [PUBMED] |
|21.||Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995;25: 433-9. [PUBMED] |
|22.||Anastassiades EG, Howarth D, Howarth J, et al. Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 1993;8:846-53. [PUBMED] [FULLTEXT]|
|23.||Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26:41-6. [PUBMED] |
|24.||Goch J, Birgegard G, Danielson BG, Wikstrom B. Iron absorption in patients with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron load test. Nephron 1996;73:403-6. |
|25.||Kooistra MP, Niemantsverdriet EC, Van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ. Iron absorption in erythropoietintreated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 1998; 13:82-8. |
|26.||O'Neill-Cutting MA, Crosby WH. The effect of antacids on the absorption of simultaneously ingested iron. JAMA 1986; 255:1468-70. |
|27.||Macdougall IC. Strategies for iron supplementation: Oral versus intravenous. Kidney Int Suppl 1999;69:S61-6. [PUBMED] |
|28.||Fishbane S, Mittal SK, Maesaka JK. Beneficial effects of iron therapy in renal failure patients on hemodialysis. Kidney Int Suppl 1999;69:S67-70. [PUBMED] |
|29.||Silverberg DS, Blum M, Peer G, Kaplan F, Iaina A. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996;72:413-7. |
|30.||Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 1996; 27:234-8. [PUBMED] |
|31.||Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-9. [PUBMED] |
|32.||Taylor JE, Peat N, Porter C, Morgan AG. Regular, low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 1996;11:1079-83. |
|33.||National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease, 2000. Am J Kidney Dis 2001;37 Suppl 1:S182-S238. |
|34.||Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999;33:464-70. [PUBMED] |
|35.||Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. BMJ 1990;300:573-8. |
|36.||McMahon LP, Johns JA, McKenzie A, Austin M, Fowler R, Dawborn JK. Hemodynamic changes and physical performance at comparative levels of hemoglobin after long-term treatment with recombinant erythropoietin. Nephrol Dial Transplant 1992;7:1199-206. [PUBMED] [FULLTEXT]|
|37.||McMahon LP, Dawborn JK. Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin. Am J Nephrol 1992;12:162-9. [PUBMED] |
|38.||Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61. [PUBMED] |
|39.||Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am J Kidney Dis 1999;33:471-82. [PUBMED] |
|40.||Sunder-Plassmann G, Horl WH. Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 1996;11:1797-802. |
|41.||Van Wyck DB, Cavallo G, Spinowitz BS, et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 2000;36:88-97. [PUBMED] |
|42.||Charytan C, Schwenk MH, Al-Saloum MM, Spinowitz BS. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clin Pract 2004;96:C63-6. [PUBMED] [FULLTEXT]|
|43.||Nissenson AR, Berns JS, Sakiewicz P, et al. Clinical evaluation of heme iron polypeptide: Sustaining a response to rHuEPO in hemodialysis patients. Am J Kidney Dis 2003;42:325-30. [PUBMED] [FULLTEXT]|
|44.||Sepandj F, Jindal K, West M, Hirsch D. Economic appraisal of maintenance parenteral iron administration in treatment of anemia in chronic haemodialysis patients. Nephrol Dial Transplant 1996;11: 319-22. [PUBMED] [FULLTEXT]|
|45.||Park L, Uhthoff T, Tierney M, Nadler S. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients. Am J Kidney Dis 1998;31:835-40. [PUBMED] |
|46.||Macdougall IC, Chandler G, Elston O, Harchowal J. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis 1999; 34:S40-S6. |
|47.||Chang CH, Chang CC, Chiang SS. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol 2002; 57:136-41. [PUBMED] |
|48.||Shaheen FA, Souqiyyeh MZ, Akeel N. Effect of intravenous iron saccharate on the requirement of erythropoietin in hemodialysis patients. Saudi J Kidney Dis Transplant 2002;13:131-40. |
|49.||Eschbach JW, Adamson JW. Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int 1999;55:35-43 (suppl 69). |
|50.||Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998;9:869-76. [PUBMED] |
|51.||Feldman HI, Santanna J, Guo W, et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002;13:734-44. [PUBMED] [FULLTEXT]|
Samir H Al-Mueilo
Department of Nephrology, King Fahd Hospital of the University, P.O. Box 40154, Alkhobar 31952
[Table - 1]